Ovarian Cancer Clinical Trials
Ovarian Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for ovarian Cancer. Corterve aggregates actively recruiting Ovarian Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Ovarian Cancer studies
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)NCT07318558PHASE3Merck Sharp & Dohme LLCOvarian NeoplasmsBirmingham, Alabama
- Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756PHASE1, PHASE2Perspective TherapeuticsPancreatic Ductal AdenocarcinomaLos Angeles, California
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsNCT05039801PHASE1M.D. Anderson Cancer CenterAdvanced Endometrial CarcinomaHouston, Texas
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsNCT06293898PHASE1SystImmune Inc.Endometrial CancerBirmingham, Alabama
- A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian CancerNCT07278336PHASE1AbbVieOvarian CancerDuarte, California
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781PHASE3Verastem, Inc.Low Grade Serous Ovarian CancerPhoenix, Arizona
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)NCT06824467PHASE3Merck Sharp & Dohme LLCOvarian CancerBirmingham, Alabama
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsNCT06586957PHASE1NiKang Therapeutics, Inc.Solid TumorLittle Rock, Arkansas
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesNCT04847063PHASE1National Cancer Institute (NCI)Peritoneal MesotheliomaBethesda, Maryland
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerNCT07059845PHASE2AbbVieOvarian CancerLa Jolla, California
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)NCT07776691PHASE3Merck Sharp & Dohme LLCOvarian CancerWashington D.C., District of Columbia
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029PHASE1Bristol-Myers SquibbAdvanced Solid TumorBirmingham, Alabama
Ovarian Cancer trials by state
Ovarian Cancer trials by metro
Frequently asked questions
- How do I find recruiting Ovarian Cancer clinical trials?
- Browse the actively recruiting Ovarian Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Ovarian Cancer clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Ovarian Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.